Impact on quality of life (QoL) of FEC-T compared with FEC or E-CMF: UK Taxotere as Adjuvant Chemotherapy Trial (TACT) 2-year follow-up
Penelope Hopwood, David Cameron(Corewell Health), L. Johnson(Michigan State University), Antonia Ridolfi, Clare Peckitt(Royal Marsden NHS Foundation Trust), Peter Ellis(Oldham Council), Emma Hall(Institute of Cancer Research), Peter Barrett‐Lee(Velindre Cancer Centre), Sarah Russell, Judith M. Bliss(Institute of Cancer Research)
Cited by 3
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k